Microbot Medical Inc. (NASDAQ:MBOT) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 1,436,514 shares, a growth of 24.4% from the July 14th total of 1,154,654 shares. Approximately 41.5% of the company’s shares are short sold. Based on an average daily trading volume, of 1,409,625 shares, the days-to-cover ratio is presently 1.0 days.

Shares of Microbot Medical (NASDAQ:MBOT) opened at 1.07 on Friday. The firm’s market cap is $39.58 million. The company’s 50-day moving average price is $1.30 and its 200 day moving average price is $3.85. Microbot Medical has a 52 week low of $1.03 and a 52 week high of $26.91.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.44. On average, equities analysts anticipate that Microbot Medical will post ($25.02) earnings per share for the current year.

In related news, major shareholder Leon Lewkowicz sold 71,224 shares of the firm’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $1.67, for a total transaction of $118,944.08. Following the sale, the insider now owns 3,078,214 shares of the company’s stock, valued at approximately $5,140,617.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.30% of the company’s stock.

An institutional investor recently raised its position in Microbot Medical stock. Bank of Montreal Can boosted its position in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 90,909.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 20,022 shares of the biotechnology company’s stock after buying an additional 20,000 shares during the period. Bank of Montreal Can owned approximately 0.07% of Microbot Medical worth $116,000 as of its most recent SEC filing. 1.13% of the stock is currently owned by hedge funds and other institutional investors.

Separately, ValuEngine raised Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.

WARNING: “Microbot Medical Inc. (MBOT) Short Interest Update” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/microbot-medical-inc-mbot-short-interest-update/1480266.html.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.